Clinical Trial Finds Yoga Eases Opioid Withdrawal and Supports Autonomic Regulation

Dr. Hemant Bhargav, associate professor of integrative medicine at India's National Institute of Mental Health and Neurosciences, known as NIMHANS, in Bengaluru, published results in JAMA Psychiatry showing that yoga added to standard buprenorphine treatment cut opioid withdrawal stabilization time from nine days to five.

The trial enrolled 59 men between ages 18 and 50, tracked between April 2023 and March 2024. Of those, 30 were assigned to receive yoga alongside buprenorphine treatment, while the remaining participants received buprenorphine alone. The yoga group completed ten supervised 45-minute sessions over 14 days, each conducted by a certified yoga therapist. The module drew on five structured components: relaxation practices, gentle asanas performed mindfully, sectional breathing techniques, and restorative sequencing, delivered daily at 11:00 am in a designated yoga hall or at bedside as needed.

More than 90% of yoga participants completed at least eight of the ten sessions. The primary outcome, measured by a Clinical Opiate Withdrawal Scale score below 4, arrived in a median of five days for the yoga group compared to nine for controls, a hazard ratio of 4.40. Breathing exercises drove respiration rates from 20 breaths per minute down to 12, a concrete autonomic shift that standard buprenorphine protocols do not directly target. The yoga group also showed measurable improvements in heart rate variability, anxiety, sleep quality, and pain scores.

"Yoga significantly accelerated opioid withdrawal recovery and improved autonomic regulation, anxiety, sleep and pain," Bhargav's team concluded. The mechanism behind those numbers matters: during opioid withdrawal, the sympathetic nervous system fires continuously while parasympathetic activity weakens. Buprenorphine manages cravings and acute symptoms but leaves that sympathovagal imbalance largely unaddressed. Yoga's breathwork and asana practice directly target that gap.

Co-authors included Matcheri Keshavan, the Stanley Cobb Professor of Psychiatry at Harvard Medical School and Beth Israel Deaconess Medical Center. The study authors note that an estimated 60 million people use opioids nonmedically worldwide, and only one in eleven of those with opioid use disorder receives any treatment.

The trial's limits are specific and worth knowing before raising it with a treatment team. The cohort was entirely male and conducted in an inpatient ward. Participants in the study misused tapentadol primarily, and while the autonomic mechanism yoga targets applies broadly across opioids, replication studies are still needed. Participants with severe withdrawal symptoms or severe psychiatric conditions were excluded from the trial entirely.

For anyone in treatment or supporting someone through it, the relevant question for a provider is whether a supervised yoga add-on is clinically appropriate given withdrawal severity, and whether a yoga therapist with clinical training in addiction settings is available. The trial's protocol required a validated module specifically designed for managing opioid use disorder withdrawal, which is structurally different from a general studio class. Certification through organizations such as the International Association of Yoga Therapists, specifically practitioners with addiction medicine experience, is the standard to look for.

NIMHANS's findings put a precise number on what the yoga community has long understood about pranayama and the nervous system: five days instead of nine, backed by a hazard ratio that gives clinicians a hard figure to work with.